ETCTN 10563: A phase I study of peposertib and liposomal doxorubicin for advanced or metastatic leiomyosarcoma and other sarcomas.
Candace L. Haddox(Rutgers, The State University of New Jersey), Suzanne George(Dana-Farber Cancer Institute), Scott M. Schuetze(University of Michigan), Ludimila Cavalcante(University of Virginia), Alice P. Chen(National Institutes of Health), Steven Gore(National Cancer Institute), Karla V. Ballman(Mayo Clinic in Arizona), Elise F. Nassif(The University of Texas MD Anderson Cancer Center), Melissa Burgess(University of Pittsburgh Medical Center), Brian Andrew Van Tine(Washington University in St. Louis), Jonathan A. Fletcher(Harvard University), Emily Jonczak(University of Miami)
Cited by 1
Related Papers
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
|Journal of the National Comprehensive Cancer Network|2010|1.2k
Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing
|Nature Genetics|2013|818
Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|733
TPM3-ALK and TPM4-ALK Oncogenes in Inflammatory Myofibroblastic Tumors
|American Journal Of Pathology|2000|716